TriClip™ TEER

MEANINGFUL
OUTCOMES BACKED BY
ROBUST EVIDENCE

TRILUMINATE™ Clinical Trial1

IMPLANT SUCCESS RATE

PROVEN SAFETY AND EFFECTIVENESS

0

Procedural
deaths

0

Procedural
strokes

0

Conversion
to surgery

90.5%

Acute procedural
success rate

0%

In-hospital
mortality

0%

Mortality
at 30 days
  • TRILUMINATE™ CLINICAL TRIAL SHOWS EFFECTIVE AND DURABLE OUTCOMES1,2

    DURABLE REDUCTION IN TRICUSPID REGURGITATION (TR)

    The proportion of subjects with moderate or less TR increased from 8% at baseline to 70% at 1 year.

  • TRILUMINATE Clinical Trial Shows Significant Improvements in Function and Quality of Life1,2

    DURABLE IMPROVEMENTS IN NYHA

  • TRICLIP™ TEER DEMONSTRATES HIGH SAFETY PROFILE2

    HIGH SURVIVAL IN A FRAGILE PATIENT POPULATION

    LOW RATES OF ADVERSE EVENTS

  • PATIENTS IN TRILUMINATE™ CLINICAL TRIAL SAW SIGNIFICANT REDUCTION IN HOSPITALIZATIONS1,2

    REDUCED HOSPITALIZATION RATE

  • Outcomes in Real-world Studies3

    The Future is bRIGHT

    bRIGHT Real-world Study Initial 30-day Results

    Proven in the largest and first Tricuspid TEER real-world study to date, the bRIGHT Study demonstrates that TriClip™ TEER significantly reduces TR with tailored therapy across diverse patient anatomies, resulting in meaningful clinical outcomes in a safe and efficient procedure.

    98%

    Implant
    Success

    90%

    Acute Procedural
    Success

    0.5%

    All-cause
    Mortality

    0.5%

    Stroke

    0.5%

    Conversion to
    Surgery

    Significant TR Reduction at 30-days

    Strong Real-world Clinical Outcomes at 30 Days

     

     

    19 POINTS
    SIGNIFICANT
    IMPROVEMENT

    in KCCQ-OS health-related quality of life

    TriClip TEER Continues to Demonstrate:

    High Procedural Success

     

    78
    ±42

    average device time (minutes)
     

    Short Device Time
    High Safety Profile 

     

    99.5% survival

    7.6% single-leaflet device
    attachment rate

    0% embolization

MAT-2006556 v4.0 | Item approved for Global OUS use only.

References
  1. Von Bardeleben RS, Lurz P, Sitges M, et al. Percutaneous edge-to-edge repair for tricuspid regurgitation: 2-year outcomes from the TRILUMINATE trial. Presented at: EuroPCR 2021
  2. Lurz P, et al. Transcatheter edge-to-edge repair for treatment of tricuspid regurgitation. J Am Coll Cardio. 2021; 77:229-23
  3. Lurz P. Schueler R., Goebel B. et al. Real-world outcomes for tricuspid edge-to-edge repair:  Initial 30-Day Results from the TriClip bRIGHT Study. Presented at: PCR London valves 2021.  

Sign up

Receive updates from Abbott Structural Heart

YOU ARE ABOUT TO ENTER AN ABBOTT COUNTRY OR REGION SPECIFIC WEBSITE.

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of the product that are not approved in other countries or regions.

YOU ARE ABOUT TO LEAVE
www.structural­heart­solutions.com

You are now leaving www.structuralheartsolutions.com. Abbott is not responsible for any content published on the third-party website you are about to enter. Abbott has not reviewed and does not endorse any information presented on third-party websites.